SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Glaxosmithkline PLC, et al. – ‘6-K’ for 5/6/08

On:  Tuesday, 5/6/08, at 9:56am ET   ·   For:  5/6/08   ·   Accession #:  1156973-8-502   ·   File #s:  1-15170, 333-149531-01, -02

Previous ‘6-K’:  ‘6-K’ on / for 5/6/08   ·   Next:  ‘6-K’ on / for 5/6/08   ·   Latest:  ‘6-K’ on / for 5/13/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/06/08  Glaxosmithkline PLC               6-K         5/06/08    2:25K                                    Bowne - Bol/FA
          Glaxosmithkline Capital Inc
          Glaxosmithkline Capital PLC

Report of a Foreign Private Issuer   —   Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report of a Foreign Private Issuer                  HTML     10K 
 2: EX-12.1     Statement re: Computation of Ratios                 HTML     17K 


6-K   —   Report of a Foreign Private Issuer


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  e6vk  

 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of May 2008
     
GlaxoSmithKline plc   GlaxoSmithKline Capital Inc.
GlaxoSmithKline Capital plc    
(Name of registrant)
980 Great West Road,
Brentford,
Middlesex, TW8 9GS
(Address of principal executive offices)
  (Name of registrant)
1105 North Market Street,
Suite 622, Wilmington,
Delaware 19801
(Address of principal executive offices)
 
Indicate by check mark if the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-Fx      Form 40-Fo
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yeso      Nox
THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN THE REGISTRATION STATEMENT ON FORM F-3 (FILE NO. 333-149531) OF GLAXOSMITHKLINE PLC, GLAXOSMITHKLINE CAPITAL INC. AND GLAXOSMITHKLINE CAPITAL PLC AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.
GlaxoSmithKline plc, GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc hereby incorporate by reference the following exhibit to this report on Form 6-K into their Registration Statement on Form F-3 (File Nos. 333-149531, 333-149531-01, 333-149531-02).
         
Exhibit No.   Description of Document  
12.1
  Statement of Computation of Ratio of Earnings to Fixed Charges.
 
 

 



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

       
Date: 6 May 2008   GlaxoSmithKline plc
      (Registrant)
 
 
 
    By: /s/  Victoria Whyte

VICTORIA WHYTE
Authorised Signatory for and on behalf of
GlaxoSmithKline plc

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘6-K’ Filing    Date    Other Filings
Filed on / For Period End:5/6/08424B2,  6-K,  FWP
 List all Filings 
Top
Filing Submission 0001156973-08-000502   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 7:05:50.2pm ET